FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220960076> ?p ?o ?g. }

• W4220960076 endingPage "421" @default.
• W4220960076 startingPage "408" @default.
• W4220960076 abstract "Excess fibroblast growth factor (FGF) 23 causes hereditary hypophosphatemic rickets, such as X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). A small molecule that specifically binds to FGF23 to prevent activation of the fibroblast growth factor receptor/<i>α</i>-Klotho complex has potential advantages over the currently approved systemically administered FGF23 blocking antibody. Using structure-based drug design, we previously identified ZINC13407541 (N-[[2-(2-phenylethenyl)cyclopenten-1-yl]methylidene]hydroxylamine) as a small molecule antagonist for FGF23. Additional structure-activity studies developed a series of ZINC13407541 analogs with enhanced drug-like properties. In this study, we tested in a preclinical <i>Hyp</i> mouse homolog of XLH a direct connect analog [(<i>E</i>)-2-(4-(<i>tert</i>-butyl)phenyl)cyclopent-1-ene-1-carbaldehyde oxime] (<b>8n</b>), which exhibited the greatest stability in microsomal assays, and [(<i>E</i>)-2-((<i>E</i>)-4-methylstyryl)benzaldehyde oxime] (<b>13a</b>), which exhibited increased in vitro potency. Using cryo-electron microscopy structure and computational docking, we identified a key binding residue (Q156) of the FGF23 antagonists, ZINC13407541, and its analogs (<b>8n</b> and <b>13a</b>) in the N-terminal domain of FGF23 protein. Site-directed mutagenesis and bimolecular fluorescence complementation-fluorescence resonance energy transfer assay confirmed the binding site of these three antagonists. We found that pharmacological inhibition of FGF23 with either of these compounds blocked FGF23 signaling and increased serum phosphate and 1,25-dihydroxyvitamin D [1,25(OH)₂D] concentrations in <i>Hyp</i> mice. Long-term parenteral treatment with <b>8n</b> or <b>13a</b> also enhanced linear bone growth, increased mineralization of bone, and narrowed the growth plate in <i>Hyp</i> mice. The more potent <b>13a</b> compound had greater therapeutic effects in <i>Hyp</i> mice. Further optimization of these FGF23 inhibitors may lead to versatile drugs to treat excess FGF23-mediated disorders. <h3>SIGNIFICANCE STATEMENT</h3> This study used structure-based drug design and medicinal chemistry approaches to identify and optimize small molecules with different stability and potency, which antagonize excessive actions of fibroblast growth factor 23 (FGF23) in hereditary hypophosphatemic rickets. The findings confirmed that these antagonists bind to the N-terminus of FGF23 to inhibit its binding to and activation of the fibroblast growth factor receptors/α-Klotho signaling complex. Administration of these lead compounds improved phosphate homeostasis and abnormal skeletal phenotypes in a preclinical <i>Hyp</i> mouse model." @default.
• W4220960076 created "2022-04-03" @default.
• W4220960076 creator A5000846104 @default.
• W4220960076 creator A5001761107 @default.
• W4220960076 creator A5023716632 @default.
• W4220960076 creator A5041433625 @default.
• W4220960076 creator A5063008659 @default.
• W4220960076 creator A5063145133 @default.
• W4220960076 creator A5063204105 @default.
• W4220960076 creator A5065514908 @default.
• W4220960076 creator A5067387007 @default.
• W4220960076 creator A5070619167 @default.
• W4220960076 creator A5077595599 @default.
• W4220960076 creator A5079804379 @default.
• W4220960076 creator A5090389433 @default.
• W4220960076 date "2022-03-26" @default.
• W4220960076 modified "2023-10-04" @default.
• W4220960076 title "Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in <i>Hyp</i> Mice" @default.
• W4220960076 cites W1800166884 @default.
• W4220960076 cites W1968628043 @default.
• W4220960076 cites W1976259152 @default.
• W4220960076 cites W1977645780 @default.
• W4220960076 cites W1989622420 @default.
• W4220960076 cites W2007039194 @default.
• W4220960076 cites W2007566466 @default.
• W4220960076 cites W2017219647 @default.
• W4220960076 cites W2023446262 @default.
• W4220960076 cites W2029667189 @default.
• W4220960076 cites W2047544498 @default.
• W4220960076 cites W2050853343 @default.
• W4220960076 cites W2058517860 @default.
• W4220960076 cites W2058721308 @default.
• W4220960076 cites W2060108666 @default.
• W4220960076 cites W2067954113 @default.
• W4220960076 cites W2073372550 @default.
• W4220960076 cites W2074473216 @default.
• W4220960076 cites W2078730571 @default.
• W4220960076 cites W2090490099 @default.
• W4220960076 cites W2091948921 @default.
• W4220960076 cites W2097302886 @default.
• W4220960076 cites W2107420262 @default.
• W4220960076 cites W2108218799 @default.
• W4220960076 cites W2124526413 @default.
• W4220960076 cites W2132742350 @default.
• W4220960076 cites W2134967712 @default.
• W4220960076 cites W2136430672 @default.
• W4220960076 cites W2148735394 @default.
• W4220960076 cites W2150341551 @default.
• W4220960076 cites W2151941626 @default.
• W4220960076 cites W2152109784 @default.
• W4220960076 cites W2155036045 @default.
• W4220960076 cites W2157448600 @default.
• W4220960076 cites W2167995070 @default.
• W4220960076 cites W2168322307 @default.
• W4220960076 cites W2270636614 @default.
• W4220960076 cites W2325488219 @default.
• W4220960076 cites W2376573086 @default.
• W4220960076 cites W2552444169 @default.
• W4220960076 cites W2755854579 @default.
• W4220960076 cites W2783547662 @default.
• W4220960076 cites W2784213390 @default.
• W4220960076 cites W2792025859 @default.
• W4220960076 cites W2800395726 @default.
• W4220960076 cites W2803769911 @default.
• W4220960076 cites W2811070535 @default.
• W4220960076 cites W2938528624 @default.
• W4220960076 cites W2994604017 @default.
• W4220960076 cites W3003636476 @default.
• W4220960076 cites W3015150755 @default.
• W4220960076 cites W3033218544 @default.
• W4220960076 cites W3099316285 @default.
• W4220960076 cites W4243935712 @default.
• W4220960076 cites W4246697500 @default.
• W4220960076 doi "https://doi.org/10.1124/molpharm.121.000471" @default.
• W4220960076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35339985" @default.
• W4220960076 hasPublicationYear "2022" @default.
• W4220960076 type Work @default.
• W4220960076 citedByCount "6" @default.
• W4220960076 countsByYear W42209600762022 @default.
• W4220960076 countsByYear W42209600762023 @default.
• W4220960076 crossrefType "journal-article" @default.
• W4220960076 hasAuthorship W4220960076A5000846104 @default.
• W4220960076 hasAuthorship W4220960076A5001761107 @default.
• W4220960076 hasAuthorship W4220960076A5023716632 @default.
• W4220960076 hasAuthorship W4220960076A5041433625 @default.
• W4220960076 hasAuthorship W4220960076A5063008659 @default.
• W4220960076 hasAuthorship W4220960076A5063145133 @default.
• W4220960076 hasAuthorship W4220960076A5063204105 @default.
• W4220960076 hasAuthorship W4220960076A5065514908 @default.
• W4220960076 hasAuthorship W4220960076A5067387007 @default.
• W4220960076 hasAuthorship W4220960076A5070619167 @default.
• W4220960076 hasAuthorship W4220960076A5077595599 @default.
• W4220960076 hasAuthorship W4220960076A5079804379 @default.
• W4220960076 hasAuthorship W4220960076A5090389433 @default.
• W4220960076 hasBestOaLocation W42209600761 @default.
• W4220960076 hasConcept C114276007 @default.
• W4220960076 hasConcept C124490489 @default.
• W4220960076 hasConcept C134018914 @default.

• next